| Name | Title | Contact Details |
|---|
With Stephen Drotter, author of The Leadership Pipeline and The Performance Pipeline, as Chairman, Leadership Pipeline Institute is the official research institute and leading global provider of solutions based on the two pipeline books, which have sold more than 300,000 copies around the world. The Leadership Pipeline institute is: • The leading global provider of Leadership Pipeline and Specialist Pipeline solutions to private and public organizations • The leading organization for research within the Leadership Pipeline and Specialist Pipeline arena • The global "magnet" for everyone with an interest in the Leadership Pipeline and Specialist concept and how it is applied Today, the Leadership Pipeline is perceived as one of the most influential leadership models through the last two decades. A significant number of the FORTUNE 500 companies have successfully implemented the Leadership Pipeline as their main leadership infrastructure for selecting and growing leaders at all levels and it has seamlessly been applied to corporate, non-profit and public organizations around the world. Leadership Pipeline Institute is specialized in supporting organizations building an internal pipeline of qualified leaders and specialists and in creating empowered, performance- and execution-focused organizations. Working with Leadership Pipeline Institute, you will receive acknowledged hands-on solutions that can be easily customized to your organization and are based on the latest applied global research and experience from some of the worlds most successful companies.
Continental Generals mission is to assist our customers with managing the financial risks and challenges that come as they age. Our skills, resources, and infrastructure allow us to help them with insulating and enhancing retirement income and maneuvering caregiving options. Thus allowing us to responsibly be a part of the solution rather than the problem. Our team of long-term care industry experts, with headquarters in Austin, Texas, strives to build value through superior operating results. As we manage our current portfolio of business, we continue to pursue growth opportunities for expansion and economies of scale through strategic acquisitions, mergers, and reinsurance opportunities. Our family of insurance companies and strategic partners provide administrative services to approximately 125,000 Long-Term Care, Life, Annuity and Supplemental Health customers. We are dedicated to upholding the commitments we have made to provide excellent service to all our customers and serve the needs of our claimants and their families during difficult times.
Antheia is a science and technology company developing next generation plant-inspired medicines.
Inspectis Digital Microscopes are elegant solutions for modern optical inspection tasks. We manufacture carefully specified Optical Systems for optimum performance, sleekly designed and made from durable high quality materials making them fit for purpose of a long life in real working environments.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.